NFL Biosciences SA (82F.F)
| Previous close | 1.9660 |
| Open | 1.9660 |
| Bid | 1.7380 x N/A |
| Ask | 1.9160 x N/A |
| Day's range | 1.9660 - 1.9660 |
| 52-week range | 0.9080 - 3.1600 |
| Volume | |
| Avg. volume | 104 |
| Market cap | 18.361M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nfl Biosciences: Patent Application Filed in the United States for Reducing Alcohol Consumption With Nfl-301 & Preparation of a Pre-Ind Application Submission With the Fda
NFL BIOSCIENCES: PATENT APPLICATION FILED IN THE UNITED STATES FOR REDUCING ALCOHOL CONSUMPTION WITH NFL-301 & PREPARATION OF A PRE-IND APPLICATION SUBMISSION WITH THE FDA NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has today submitted a patent application in the United States for its drug candidate NFL-301, focused on reducing alcohol consumption. This patent applica
- GlobeNewswire
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, has been informed that 50,000 BSPCE company founder warrants (“BSPCE warrants”) held by Mr Bruno Lafont, Chief Operating Officer and co-founder of NFL Biosciences, have been exercised, giving him the right to subscribe 500,000 new shares, enabl
- GlobeNewswire
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical medicines for the treatment of drug dependencies and addictions, has been informed of the exercise of 100,000 share subscription warrants ("BSA") held by GB Holding, the holding company of Mr Gérard Leduc, resulting in
